Crescent Capital Consulting LLC boosted its holdings in GlaxoSmithKline plc (NYSE:GSK) by 19.9% during the first quarter, Holdings Channel.com reports. The firm owned 2,414 shares of the pharmaceutical company’s stock after acquiring an additional 400 shares during the quarter. Crescent Capital Consulting LLC’s holdings in GlaxoSmithKline were worth $85,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Dodge & Cox raised its stake in GlaxoSmithKline by 39.9% during the fourth quarter. Dodge & Cox now owns 62,935,758 shares of the pharmaceutical company’s stock valued at $2,316,036,000 after buying an additional 17,935,102 shares during the last quarter. Fisher Asset Management LLC raised its holdings in shares of GlaxoSmithKline by 1.9% during the fourth quarter. Fisher Asset Management LLC now owns 16,526,594 shares of the pharmaceutical company’s stock valued at $608,179,000 after purchasing an additional 300,377 shares during the last quarter. Black Creek Investment Management Inc. lifted its position in GlaxoSmithKline by 14.8% during the fourth quarter. Black Creek Investment Management Inc. now owns 7,443,061 shares of the pharmaceutical company’s stock valued at $273,905,000 after purchasing an additional 957,185 shares during the period. Morgan Stanley boosted its holdings in GlaxoSmithKline by 12.3% in the fourth quarter. Morgan Stanley now owns 3,794,274 shares of the pharmaceutical company’s stock worth $139,629,000 after purchasing an additional 416,656 shares during the last quarter. Finally, Nuveen Asset Management LLC raised its stake in GlaxoSmithKline by 891.0% during the 4th quarter. Nuveen Asset Management LLC now owns 2,328,072 shares of the pharmaceutical company’s stock valued at $85,673,000 after buying an additional 2,093,158 shares during the last quarter. Hedge funds and other institutional investors own 11.83% of the company’s stock.
NYSE:GSK opened at $37.75 on Monday. GlaxoSmithKline plc has a fifty-two week low of $33.26 and a fifty-two week high of $43.18. The company has a quick ratio of 0.61, a current ratio of 0.90 and a debt-to-equity ratio of 1.13. The stock has a market cap of $101.65 billion, a PE ratio of 11.62, a price-to-earnings-growth ratio of 2.93 and a beta of 0.67. The firm’s fifty day simple moving average is $35.72 and its 200-day simple moving average is $36.54.
GlaxoSmithKline (NYSE:GSK) last released its earnings results on Tuesday, February 2nd. The pharmaceutical company reported $0.62 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.64 by ($0.02). GlaxoSmithKline had a return on equity of 29.60% and a net margin of 18.50%. The business had revenue of $8.74 billion for the quarter, compared to analysts’ expectations of $8.71 billion. During the same quarter last year, the company posted $0.39 earnings per share. The business’s quarterly revenue was down 1.8% compared to the same quarter last year. Equities analysts anticipate that GlaxoSmithKline plc will post 3.07 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, April 8th. Investors of record on Friday, February 19th were given a dividend of $0.628 per share. This represents a $2.51 dividend on an annualized basis and a yield of 6.65%. The ex-dividend date of this dividend was Thursday, February 18th. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.50. GlaxoSmithKline’s dividend payout ratio is 79.50%.
A number of research analysts have weighed in on GSK shares. Barclays reissued an “underweight” rating on shares of GlaxoSmithKline in a report on Friday, February 5th. Berenberg Bank reaffirmed a “buy” rating on shares of GlaxoSmithKline in a report on Thursday, February 11th. UBS Group reissued a “neutral” rating on shares of GlaxoSmithKline in a research report on Monday, February 8th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research report on Tuesday, February 9th. Finally, Credit Suisse Group cut shares of GlaxoSmithKline from a “neutral” rating to an “underperform” rating in a research report on Wednesday, January 20th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the company. GlaxoSmithKline presently has a consensus rating of “Hold” and an average target price of $41.00.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.